EUPRAXIA PHARMACEUTICALS INC. (EPRX) SEC Filings

Eupraxia Pharmaceuticals Inc. (EPRX) has filed an amended Form F-10 short form base shelf prospectus to register up to US$300,000,000 of common shares, preferred shares, debt securities, warrants, subscription receipts and units. Securities may be offered by Eupraxia or selling securityholders, separately or together, over a 25‑month period, including via underwritten deals, private sales or an at‑the‑market distribution.

Eupraxia is a clinical‑stage biotechnology company using its Diffusphere™ delivery technology, with lead programs EP‑104GI for eosinophilic esophagitis and EP‑104IAR for knee osteoarthritis. As of June 30, 2026, it held $52.4 million in cash and cash equivalents and anticipates funding operations into the second half of 2028, while disclosing a history of negative operating cash flow and ongoing capital needs.

The prospectus highlights significant risks, including speculative investment characteristics, dilution from additional equity, limited liquidity in some securities, PFIC-related U.S. tax exposure, dependency on EP‑104GI and EP‑104IAR development and the challenges of obtaining regulatory approvals across multiple jurisdictions under the MJDS framework.

Manchester Management Company, LLC, Manchester Management PR, LLC, Manchester Explorer, L.P., James E. Besser, and Morgan C. Frank report their ownership of common shares of Eupraxia Pharmaceuticals Inc. on an amended Schedule 13G (Amendment No. 3).

Reported beneficial ownership includes 2,634,048 shares (4.3% of the class) for each of Manchester Management Company, LLC and Manchester Management PR, LLC, 2,511,121 shares (4.1%) for Manchester Explorer, L.P., 2,772,341 shares (4.5%) for James E. Besser, and 2,664,780 shares (4.3%) for Morgan C. Frank. Besser has sole voting and dispositive power over 138,293 shares and Frank over 153,659 shares, with the remainder held under shared voting and dispositive power.

The filing states that, other than the shares over which Besser and Frank have sole power, all reported securities are directly owned by advisory clients of Manchester Management PR, LLC and that none of these advisory clients may be deemed to beneficially own more than 5% of Eupraxia’s common shares. Each reporting person disclaims beneficial ownership beyond their pecuniary interest.

Eupraxia Pharmaceuticals Inc. reported new symptom-response data from the Phase 1b/2a RESOLVE trial of EP-104GI in adults with eosinophilic esophagitis. In Cohorts 7–9, the proportion of patients with moderate or severe odynophagia fell from 62% at baseline to 25% at 24–52 weeks, and severe odynophagia (23% at baseline) was absent at 24 and 52 weeks. For dysphagia, moderate or severe symptoms decreased from 77% at baseline to 25% at 24 and 52 weeks. At 52 weeks, 50% of patients reported no odynophagia versus 15% at baseline. EP-104GI has been administered to over 130 patients (more than 2,000 injection sites) with no treatment-emergent or procedure-related Serious Adverse Events reported. A randomized Phase 2b portion of RESOLVE using 120 mg and 160 mg doses is ongoing, with an interim readout expected in Q4 2026.

Eupraxia Pharmaceuticals Inc. reported a six-month 2026 net loss of $27.1 million, wider than $15.5 million a year earlier, driven by sharply higher research and development spending of $24.0 million and general and administrative expenses of $10.1 million as EP‑104GI and platform programs advanced.

Liquidity strengthened after a February 20, 2026 overnight marketed equity offering of 7,607,145 common shares and 1,428,571 pre‑funded warrants, generating about $58.6 million net. At June 30, 2026, cash and cash equivalents were $52.4 million and short‑term investments $81.2 million, versus current liabilities of $8.6 million.

The company remains pre‑revenue with an accumulated deficit of $196.7 million and discloses continued dependence on external financing, partnerships and potential non‑dilutive funding. Clinical work focuses on the RESOLVE trial of EP‑104GI for eosinophilic esophagitis, while development and partnering for EP‑104IAR for osteoarthritis are currently paused.

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company based in Vancouver, has filed a short form base shelf prospectus and accompanying Form F-10 to register up to US$300,000,000 of common shares, preferred shares, debt securities, warrants, subscription receipts and units. These securities may be offered over a 25‑month period by the company or its securityholders, separately or together, including through underwritten offerings or an at-the-market distribution. Common shares trade on the TSX and Nasdaq under “EPRX,” with recent closing prices of C$8.98 and US$6.51, respectively. The filing highlights significant risks, including potential dilution from additional equity, limited liquidity for non-common-share securities, PFIC-related U.S. tax consequences, dependence on lead candidates EP‑104GI and EP‑104IAR, and the need for substantial additional capital.

Eupraxia Pharmaceuticals Inc. announced significant updates to its executive leadership and operating structure as it prepares for its next stage of clinical and commercial development. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, effective July 13, 2026, and Dr. Alex Therien will lead Research & Development in his role as Executive Vice President, Research & Development.

The company has transitioned its operations from Victoria to Vancouver and Seattle, evolving into a cross-border two-hub organization. Key clinical, manufacturing and commercial executive roles, including the CEO, will be based in Seattle. As part of this transition, Amanda Malone stepped down as Chief Scientific and Operating Officer effective July 10, 2026.

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, reported changes to its executive leadership and operating structure to support upcoming clinical and commercial milestones. Dr. Jeff Millard has joined as Executive Vice President, Technical Operations effective July 13, 2026, bringing nearly 25 years of experience in technical operations, CMC and regulatory strategy. Dr. Alex Therien, who joined in November 2025, will lead Research & Development as Executive Vice President, Research & Development, with responsibility for portfolio expansion.

The company has transitioned operations from Victoria to Vancouver and Seattle, with key clinical, manufacturing and commercial leaders, including the CEO, based in Seattle to support growing clinical operations. As part of this shift, Amanda Malone, based in Victoria, stepped down as Chief Scientific and Operating Officer effective July 10, 2026. Eupraxia is preparing for a Q4 2026 interim data release from its RESOLVE Phase 1b/2 trial of EP-104GI in Eosinophilic Esophagitis and is planning for potential Phase 3 development, regulatory, manufacturing and commercialization activities. The company also highlights prior Phase 2b SPRINGBOARD trial results for EP-104IAR in knee osteoarthritis, where the study met its primary endpoint and three of four secondary endpoints, and notes a broader pipeline of long-acting formulations using its Diffusphere™ drug delivery platform.

Eupraxia Pharmaceuticals Inc. filed a Form 6-K to share a press release announcing three new appointments to its Board of Directors: Robert Bazemore, Amy Pott and Dr. Helen Thackray. These directors bring deep experience in late-stage drug development, commercialization and global product launches across oncology, rare disease and gene therapy.

The company highlights its proprietary Diffusphere™ technology for localized, extended-release drug delivery and provides an update that EP-104GI is in a Phase 1b/2 RESOLVE trial for eosinophilic esophagitis, while EP-104IAR met the primary endpoint and most secondary endpoints in a Phase 2b knee osteoarthritis trial.

Eupraxia Pharmaceuticals Inc. reported the results of its Annual General Meeting held on June 18, 2026. Shareholders approved setting the board size at seven directors and elected all seven management nominees, each receiving strong support, with most candidates above 97% of votes cast in favour.

Shareholders also re-appointed KPMG LLP as the Company’s auditor for the ensuing year and authorized the board to fix the auditor’s pay, with more than 99% of votes cast in favour. These outcomes maintain board continuity and the existing audit relationship for the next year.